Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Viridian TherapeuticsSTU:1S1 -1.49%52 FCF Margin % is -37,471.66% as of Jun. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 52/100. The stock has 5 warning signs investors should review. Among 953 Biotechnology companies, Viridian Therapeutics ranks worse than 71.88% on this metric.
Viridian Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Viridian Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1S1 vs BHVN, AGIO, SION: FCF Margin % Comparison
For the Biotechnology subindustry, Viridian Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viridian Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Viridian Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viridian Therapeutics (STU:1S1) has a FCF Margin % of -37,471.66% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viridian Therapeutics and its competitors. According to the industry distribution chart, Viridian Therapeutics ranks #685 out of 953 companies in the Biotechnology industry, placing it in the top 71.9%.
Is Viridian Therapeutics' FCF Margin % too high?
Viridian Therapeutics' current FCF Margin % is -37,471.66%. Based on the distribution chart, Viridian Therapeutics ranks #685 out of 953 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Viridian Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' FCF Margin % compare to BHVN and AGIO?
According to the Biotechnology industry distribution chart, Viridian Therapeutics ranks #685 out of 953 companies for FCF Margin %. This places Viridian Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current FCF Margin % is -37,471.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (STU:1S1) has a current FCF Margin % of -37,471.66%. The current FCF Margin % is -37,471.66%. Viridian Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current FCF Margin % is -37,471.66% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
52GF Score
Get the complete analysis for STU:1S1
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1S1 has been successfully added to your 
